GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
- Conditions
- Metastatic Breast CancerNeoplasms, Breast
- First Posted Date
- 2003-01-06
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00051103
- Locations
- πΊπΈ
GSK Investigational Site, Salem, Virginia, United States
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- First Posted Date
- 2002-11-20
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 760
- Registration Number
- NCT00049998
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Major Depressive Disorder Study In Adults
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-11-19
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 646
- Registration Number
- NCT00049972
- Locations
- πΊπΈ
GSK Clinical Trial Call Center, Kirkland, Washington, United States
Schizophrenia Study In Adults
- Conditions
- Schizophrenia
- First Posted Date
- 2002-11-18
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 231
- Registration Number
- NCT00049946
- Locations
- πΊπΈ
GSK Clinical Trial Call Center, Terrell, Texas, United States
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
- Conditions
- Attention Deficit Disorder
- First Posted Date
- 2002-10-31
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 162
- Registration Number
- NCT00048360
- Locations
- πΊπΈ
GSK Clinical Trials Call Center, Seattle, Washington, United States
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2002-10-30
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 372
- Registration Number
- NCT00048204
Prevention of Seasonal Affective Disorder
- Conditions
- Seasonal Affective Disorder (SAD)
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00046449
- Locations
- πΊπΈ
Study SIte, Greenwood, Indiana, United States
π¨π¦Study Site, Hull, Quebec, Canada
A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2002-09-30
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00046332
- Locations
- πΊπΈ
GSK Clinical Trials Call Center, Houston, Texas, United States
Prevention of Seasonal Affective Disorder
- Conditions
- Seasonal Affective Disorder
- First Posted Date
- 2002-09-25
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00046241
- Locations
- π¨π¦
GSK Clinical Trials Call Center, Sherbrooke, Quebec, Canada
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT00046111
- Locations
- π¨π¦
GSK Investigational Site, Ottawa, Ontario, Canada